Scarica l'app Stockscreener
114.23
1.06%
1.20
Dopo l'orario di chiusura:
114.28
0.05
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360
AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma
Gilead price collects profitsForecast today29-07-2025 - Economies.com
Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com
Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Why Gilead Sciences Stock Slipped Today - Yahoo Finance
Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha
Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits
Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com
Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily
TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey
Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu
Gilead Sciences Stock Surges Amid Promising Trials - TipRanks
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Why Gilead Sciences Stock Just Popped - The Motley Fool
Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Benzinga
EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus
Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha
What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits
Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha
Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace
Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria
Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest
Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org
Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia
What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Is Gilead Sciences Inc. stock a growth or value playTremendous gains - jammulinksnews.com
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace
Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks
Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks
Looking Back to the Future: Gilead’s Long-Standing Commitment To Help End the HIV Epidemic - CSRwire
Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)
AG Jackson announces major settlement with Gilead Sciences over kickbacks - WPDE
Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView
Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic - The Hollywood Reporter
Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic - ACCESS Newswire
What to Expect From Gilead Sciences’ Q2 2025 Earnings Report - MSN
What To Expect From Gilead Sciences’ Q2 2025 Earnings Report - Barchart.com
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update - TipRanks
Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda - insights.citeline.com
0.04%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):